REBLOZYL (luspatercept-aamt) is an erythroid maturation agent indicated for the treatment of anemia in adult patients with beta thalassemia requiring regular transfusions and in various myelodysplastic syndromes, demonstrating efficacy in reducing transfusion burden and improving hemoglobin levels.

Mechanism and Clinical Applications in Transfusion-Dependent Anemias

REBLOZYL is approved for three primary therapeutic applications:

Treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions

Treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular RBC transfusions

Treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk MDS-RS or MDS/MPN-RS-T